Astral demerger plan: JPMorgan cuts target to ₹1,600

What changed for Astral investors

Astral Ltd is facing a busy period on two fronts: a corporate restructuring that will split its chemicals business, and a reset in Street expectations after a key brokerage downgrade. JPMorgan analyst Rishabh Gupta downgraded Astral (ASTRA:IN) from Overweight to Neutral and cut the price target to ₹1,600 from ₹1,800.

The move lands at a time when Astral has announced a major reorganisation. The company said it will demerge its chemicals business into a separately listed entity, Astral Chemie, while amalgamating Al-Aziz Plastics into Astral. The plumbing business will remain within the existing listed entity.

JPMorgan downgrade and revised target

JPMorgan’s change in stance is clear: the stock is now rated Neutral, and the target price has been reduced to ₹1,600. The earlier target mentioned in the same context was ₹1,800.

Separate brokerage snapshots in the provided data also show earlier JPMorgan positioning around Astral, including references to initiation of coverage with an Overweight rating and a ₹1,700 target, and a separate listing that shows JPMorgan with a “Buy” stance and a ₹1,800 target on Jun 02, 2026. These data points indicate JPMorgan’s view has not been static, with the latest update reflecting more caution.

For investors, the immediate implication is that valuation comfort and near-term triggers have become central to the debate, even as the restructuring introduces a new listed entity and a potentially clearer segment split.

Astral’s restructuring: demerger and amalgamation

Astral has announced a restructuring led by:

• Demerger of its chemicals business into a separately listed company, Astral Chemie
• Amalgamation of Al-Aziz Plastics into Astral
• Retention of the plumbing business in the existing listed company

The company said the demerger is subject to regulatory approval. Once approvals are in place, Astral Chemie is scheduled to be listed on both NSE and BSE.

This kind of structure typically aims to separate business profiles that can attract different investor bases. In Astral’s case, the plumbing and pipes profile stays in the current entity, while the chemicals business is expected to be housed in the new listed company.

Where the stock is trading

Astral’s stock price in the provided data set was ₹1,486.90, down ₹49.80 or 3.24% (as on 25 Jun, 2026 | 04:03). Another data point states that as of Jun 28, 2026, Astral was trading at ₹1,486.90 with a previous close of ₹1,536.70.

The price context matters because several analyst targets and valuation references in the data cluster around the ₹1,600 to ₹1,800 range, creating a fairly narrow band that investors will likely track alongside restructuring milestones.

Valuation discussion: premiums versus peers

A valuation comparison in the provided text highlights that Astral, on an FY28 basis, trades at a premium to Supreme Industries and Finolex Industries on price-to-earnings.

Key valuation points cited include:

• Astral trading at 44x price-to-earnings for FY28
• On EV/EBITDA, Astral at a premium of 20% compared to Supreme Industries
• Pidilite Industries referenced at 52x price-to-earnings for FY28
• Pidilite EV/EBITDA referenced at 36x

The same discussion frames valuation as a key variable to watch after the restructuring narrative and as investors compare Astral’s multiples to other building-material and adhesives-linked names.

Analyst targets: a wide spread across the Street

The data includes multiple target prices from different brokerages and aggregators:

• Anand Rathi: “Buy Astral; target of ₹1,800” (May 21, 2026)
• Prabhudas Lilladher: targets of ₹1,863 (May 21, 2026) and ₹1,813 (May 19, 2026)
• Motilal Oswal: “Buy Astral; target of ₹1,650”
• Mirae Asset Sharekhan: “Buy Astral; target of ₹1,643”

There is also an “Analysts 12-Month Price Target” average of ₹1,763.62, shown with an upside of +18.61%. Another set of consensus numbers states an average 12-month price target of ₹1,763.62 with a high estimate of ₹2,150 and a low estimate of ₹1,378, and an overall rating of Buy with 23 analysts recommending buy and 1 suggesting sell.

Separately, a different consensus snapshot in the same dataset mentions a “Moderate Buy” consensus with a price target consensus of ₹1,620.29.

Upcoming results: estimates and calendar

Astral’s next earnings report date in the provided text is Nov 7, 2025, with the report period listed as Q2 2025.

Estimates shown include:

• EPS estimate: ₹4.15
• Revenue estimate: ₹1,474 crore (converted from ₹14.74 billion)

Another line item notes a brokerage expectation that Astral’s Q2 PAT may dip 8.3% year-on-year to ₹99.7 crore (attributed to Prabhudas Lilladher in the provided text).

Key numbers at a glance

Market impact: what investors are watching

The combined effect of a restructuring announcement and a high-profile downgrade tends to shift near-term focus from broad growth narratives to execution detail. In Astral’s case, the event set includes regulatory approvals, the mechanics of the listing of Astral Chemie, and how the market values the two entities once separated.

At the same time, the valuation discussion cited in the material shows Astral already trades at a premium to some peers on FY28 multiples. That context helps explain why targets are being revisited and why investors may weigh the separation benefits against premium valuations.

The stock’s move to ₹1,486.90 with a 3.24% drop on the cited day also highlights that positioning can change quickly as investors digest both restructuring complexity and changes in brokerage stances.

Why the development matters

Astral’s demerger plan is not just a corporate action. It potentially changes how investors model the business, compare it with peers, and apply valuation multiples across segments. A separately listed Astral Chemie may allow the market to value the chemicals business distinctly from plumbing and pipes, while the amalgamation of Al-Aziz Plastics consolidates operations under the existing listed vehicle.

JPMorgan’s downgrade to Neutral and reduction in target price adds a valuation lens to this transition. With multiple target prices clustering between ₹1,600 and ₹1,863 in the provided data, the market appears to be weighing both near-term earnings expectations and the longer-term benefit of a cleaner structure.

Conclusion

Astral’s announced demerger of its chemicals business into Astral Chemie, along with the amalgamation of Al-Aziz Plastics, sets up a significant corporate reshuffle subject to regulatory approvals and a planned NSE and BSE listing. Against that backdrop, JPMorgan’s downgrade to Neutral and target cut to ₹1,600 from ₹1,800 puts valuation discipline back at the centre of the investment debate. The next set of company updates on the demerger process and the upcoming earnings calendar milestones will be key reference points for investors tracking the stock.